[1] DEL RIO C. Current concepts in antiretroviral therapy failure [J]. Top HIV Med，2006，14(3)：102-106. [2] SRIVASTAVA S，SLUIS-CREMER N，TACHEJIAN G. Dimerization of human immunodeficiency virus type 1 reverse transcriptase as an antiviral target [J]. Curr Pharm Des，2006，12(15)：1879-1894. [3] BALZARINI J，AUWERX J，RODRIGUEZ-BARRIOS F，et al. The amino acid N136 in HIV-1 reverse transcriptase (RT) maintains efficient association of both Rtsubunits and enables the rational design of novel RT inhibitors [J]. Mol Pharmacol，2005，68(1)： 49-60. [4] AUWERX J，YAN-NIEUWENHOVE J，RODRIGUEZ-BARRIOS F，et al. The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs [J]. FEBS Letters，2005，579(11)： 2294-2300. [5] JANSSEN P A，LEWI P J，ARNOLD E，et al. In search of a novel anti-HIV drug：multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474，Rilpivirine) [J]. J Med Chem，2005，48(6)：1901-1909. [6] BELOV D A，VESELOVSKII A V. Analysis of contact interfaces of HIV reverse transcriptase subunits [J]. Biomed Khim，2006，52(1)：19-28. [7] ALOK MULKY，CHRISTIE VU B，CONWAY JOAN A，et al. Analysis of amino acids in the β7-β8 loop of human immunodeficiency virus type 1 reverse transcriptase for their role in Virus Replication[J]. J Mol Biol，2007，365(5)： 1368-1378. [8] LEVY Y，CAFLISCH A，ONUCHIC J N，et al. The folding and dimerization of HIV-1 protease：Evidence for a stable monomer from simulations [J]. J Mol Biol，2004，340(1)：67-79. [9] SLUIS-CREMER N，ARION D，ABRAM M E，et al. Proteolytic processing of an HIV-1 pol polyprotein precursor：insights into the mechanism of reverse transcriptase p66/p51 heterodimer formation [J]. Int J Biochem Cell Biol，2004，36(9)：1836–1847. [10] DE SOULTRAIT V R，DESJOBERT C，TARRAGO-LITVAK L.Peptides as new inhibitors of HIV-1 reverse transcriptase and integrase [J].Curr Med Chem，2003，10(18)：1765-1778. [11] DIVITA G，RESTLE T，GOODY R.S，et al. Inhibition of human immunodeficiency virus type 1 reverse transcriptase dimerization using synthetic peptides derived from the connection domain[J]. J Biol Chem，1994，269(18)：13080-13083. [12] MORRIS M C，ROBERT-HEBMANN V，CHALOIN L，et al. A new potent HIV-1 reverse transcriptase inhibitor. A synthetic peptide derived from the interface subunit domains[J]. J Biol Chem，1999，274(35)： 24941-24946. [13] DEPOLLIER J，HOURDOU M L，ALDRIAN-HERRADA G，et al. Insight into the mechanism of a peptide inhibitor of HIV reverse transcriptase dimerization [J]. Biochemistry，2005，44(6)： 1909-1918. [14] MORRIS M C，BERDUCOU C，MERY J，et al. The thumb domain of the P51-subunit is essential for activation of HIV reverse transcriptase [J].Biochemistry，1999，38(46)： 15097-150103. [15] CAMARASA M J，VELAZQUEZ S，SAN-FELIX A，et al. TSAO derivatives，inhibitors of HIV-1 reverse transcriptase dimerization： recent progress [J]. Curr Pharm Des，2006，12(15)： 1895-1907. [16] CAMARASA M J，VELAZQUEZ S，SAN-FELIX A，et al. TSAO derivatives the first non-peptide inhibitors of HIV-1 RT dimerization [J]. Antivir Chem Chemother，2005，16(3)： 147-153. [17] RODRIGUEZ-BARRIOS F，PEREZ C，LOBATON E，et al. Identification of a putative binding site for [2',5'-bis- O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1''，2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase [J]. J Med Chem，2001，44(12)：1853-1865. [18] CAMARASA M J，VELAZQUEZ S，SAN-FELIX A，et al. Dimerization inhibitors of HIV-1 reverse transcriptase，protease and integrase：A single mode of inhibition for the three HIV enzymes[J]. Antiviral Research，2006,71(2-3)：260-267. [19] AUWERX J，RODRIGUEZ-BARRIOS F，CECCHERINI- SILBERSTEIN F，et al. Role of T139 in the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) sensitivity to (+)-calanolide A [J]. Mol Pharmacol，2005，68(3)： 652-659. [20] SLUIS-CREMER N，HAMAMOUCH N，SAN FELIX A，et al. Structure-activity relationships of [2',5'-bis-O-(tert-butyldimethyl- silyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'，2''-oxathiole- 2''，2''-dioxide)thymine derivatives as inhibitors of HIV-1 reverse transcriptase dimerization [J]. J Med Chem，2006，49(16)： 4834-4841. [21] BONACHE M C，CHAMORRO C，VELAZQUEZ S，et al. Improving the antiviral efficacy and selectivity of HIV-1 reverse transcriptase inhibitor TSAO-T by the introduction of functional groups at the N-3 position [J]. J Med Chem，2005，48(21)： 6653-6660. [22] SLUIS-CREMER N，ARION D，MICHAEL A P. Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors [J]. Mol Pharmacol，2002，62(2)：398-405.